Loading data for APVO — first visit, this takes a few seconds.
Aptevo Therapeutics Inc. (APVO)
NasdaqCM: APVO
· Real-Time Price · USD
2.68
-0.08 (-2.90%)
At close: Aug 24, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Aptevo Therapeutics Inc. (APVO) Stock Price, Analysis & Data
-2.90% (1D)
No data available
| Bid | 2.04 |
| Market Cap | 4.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.5M |
| 1.65 | |
| 456.62 | |
| 0.01 | |
| -0.23 | |
| P/B (ttm) | 0.57 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.37 |
| Volume | 53,273 |
| Avg. Volume (20D) | 54,964 |
| Open | 2.84 |
| Previous Close | 2.76 |
| Day's Range | 2.58 - 2.85 |
| 52-Week Range | 2.58 - 48.78 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical bloo...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2016
Employees 33
Stock Exchange NasdaqCM
Ticker Symbol APVO
Website https://aptevotherapeutics.com
Financial Performance
In 2025, Aptevo Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -25.97M, an increase of 7.61%.
Financial StatementsEarnings Surprise
Aptevo Therapeutics has released their quarterly earnings on Aug 14, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -5.31 exceeds estimates by 0.89, with 99.66% YoY growth.
